Vistagen Therapeutics Q3 2024 Earnings Call Transcript

Quartr
Provided by Quartr
February 13, 2024

There are 7 speakers on the call.

Operator

Greetings, and welcome to the Vistigen Therapeutics Fiscal Year 20 24 Third Quarter Financial Results and Corporate Update. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce Mark McPartland, Senior Vice President, Investor Relations at Vistigen.

Operator

Thank you. You may begin.

Speaker 1

Thank you, Doug. Good afternoon, everyone, and welcome to Vistigen's fiscal year 2020 Q3 Corporate Update Conference Call and Webcast. This afternoon, we filed our quarterly report and issued a press release providing an overview of our recent Q3 results and our neuroscience pipeline development. We encourage you to review the release, which can be found in the Investor Relations section of the Vistigen website. During today's call, we'll make forward looking statements regarding our business based on our current expectations and information.

Speaker 1

The forward looking statements speak only as of today and except As required by law, we do not assume any duty to update in the future any forward looking statement made today. Of course, forward looking statements involve risks and uncertainties, and our actual results could differ materially from those anticipated any forward looking statements we make today. Additional information concerning risks and factors that could affect our business and financial results are included in our fiscal year 2024 Q3 Form 10 Q for the period ending December 34, 2023, and in future filings that we make with the SEC from time to time, all of which are or will be available on our website and the SEC's website. Now with that taken care of, I'd like to thank and welcome all our stockholders, analysts and everyone taking an interest in Vistigen. I'm joined on the call today by Sean Singh, our Chief Executive Officer Cindy Anderson, our Chief Financial Officer and Josh Prince, our Chief Operating Officer.

Speaker 1

Sean will provide an overview of our recent results and our progress across our key pipeline programs. A brief opportunity for questions from sell side analysts will follow their prepared remarks. I'd like to remind everyone this call is being webcast and will be available for replay after completion. The replay link can be found in the Investor Events section of the Vistigen website. I would now like to turn the call over to our Chief Executive Officer, Sean Singh.

Speaker 1

Sean?

Speaker 2

Thank you, Mark, and good afternoon, everyone. Thank you for joining our call today. Here at Visagen, we are pioneering neuroscience with an intention to deliver 1st in class therapies for psychiatric and neurological disorders where there are few if any adequate and differentiated FDA approved treatment options to satisfy the widespread needs of patients whose mental health and whose well-being are adversely affected by their disorders. Each of our clinical stage neuroscience product candidates is designed with the potential to establish new standards of care and make meaningful differences in how patients manage their disorders to improve their daily lives. Within the last few months, we've seen a renaissance in neuroscience marked notably by pharma M and A in the neuropsychiatry space valued at about $23,000,000,000 We are encouraged that novel late stage neuroscience derived product candidates with Differentiated safety profiles have stimulated renewed interest in large market neuropsychiatry programs with the potential to change lives.

Speaker 2

We believe each of our clinical neuroactive pharynx led by Fasadienol for the acute treatment of social anxiety disorder is anchored in novel neuroscience and has the potential to produce differentiated product profiles across multiple and diverse large market therapeutic areas with high need for innovation and high need to transform the standards of care including anxiety, depression, women's health and other disorders. Today we'll briefly discuss our progress and plans for 3 of these 3 of our 5 faring assets in our clinical stage neuroscience pipeline, vasodenol, Itruvone and PH80. As noted, our lead clinical stage program involves fasodionol and is aimed at transforming the treatment paradigm for adults affected by social anxiety disorder or SAD, which currently affects the lives of about 10% of the U. S. Adult population with very high opportunity cost in their daily life.

Speaker 2

While the prevalence of SAD continues to grow, There's still no FDA approved patient tailored acute treatment option to help individuals with SAD rapidly and safely address their anxiety when their stressors are upon them in their daily life. With the positive results from our PALISADE II Phase III trial reported last year and a strong balance sheet, we're fully focused on advancing our PALISADE Phase 3 development program in SAD with preparations to initiate This year all key remaining studies planned for that program. Since our last conference call in November, our team has been diligently focused on the preparations necessary to initiate PALISADE III, which will be our next Phase III clinical trial of in adults with social anxiety disorder. That remains on track to begin in the first half of twenty twenty four. That will be followed by PALISADE 4 to be initiated in the second half of this year.

Speaker 2

PALISADE 3 and PALISADE 4 will be similar to our successful PALISADE II Phase III trial. Both trials will involve a public speaking challenge in a clinical setting with patient reported outcomes on the subjective units of distress scale or SUDs is the primary efficacy endpoint. We believe either PALISADE III or PALISADE IV if successful together with the positive results from PALISADE II may establish substantial evidence of effectiveness of Fasadienol in support of a potential NDA submission for the acute treatment of anxiety in adults with SAD. Last year we accomplished something that to our knowledge had never been achieved And that is to demonstrate positive Phase 3 results in an anxiety study with a drug candidate that does not need to be taken up systemically or act directly on neurons in the brain. We look forward to getting back into the clinic soon with PALISADE III to continue driving on our mission to deliver a 1st in class therapy in a large neuropsychiatry market in need of differentiated fast acting therapies without the risk of sexual side effects, weight gain or abuse liability concerns.

Speaker 2

Beyond fasidienol in our Phase 3 program In SAD, we are continuing to explore various ways to unlock the significant potential of our Atruvone asset As a differentiated new therapy for major depressive disorder or MDD, preparations and planning for potential U. S. Phase 2b trial by Truvone Monotherapy in MDD are ongoing. Again, our mission in this large and unfortunately increasing neuropsychiatry market is to deliver a differentiated therapy to transform the standard of care without the risk of sexual side effects, weight gain or abuse liability concerns. We also see great potential in our rapid onset hormone free PH80 nasal spray.

Speaker 2

Its potential is anchored in the previously unreported positive results from 2 trials in women's health indications that we announced last year. 1st is a treatment for vasomotor symptoms or hot flashes due to menopause and next for the management of Premensural Dysphoric disorder or PMDD. PHAD showed statistically significant results in both studies. We are preparing to conduct Non clinical studies necessary to submit a U. S.

Speaker 2

IND to facilitate further Phase 2 clinical development of PH-eighty for women's health indications including the treatment of patients with moderate to severe vasomotor symptoms or hot flashes that are due to menopause. I'll now turn the call over to our CFO, Cindy Anderson, to summarize some of the highlights from our financial results for the Q3 of our fiscal 'twenty four. Cindy?

Speaker 3

Thank you, Sean. As Sean mentioned, I will highlight a few financial results from our fiscal year 2024 Q3. I also encourage everyone to review our quarterly report on Form 10 Q filed with the SEC earlier this afternoon for additional details and disclosures. Research and development expense was $4,500,000 $6,900,000 for the 3 months ended December 31, 2023 and 2022 respectively. The decrease in R and D expense was primarily due to a decrease in clinical and development expenses related to the timing of such expenses incurred in our Phase III trials of Fezonylodal and SAB.

Speaker 3

General and administrative expense was $3,800,000 for the 3 month period ended December 31, 2023, compared to $3,100,000 for the period prior year period. The increase was primarily due to the increase in compensation related expenses. Our net loss attributable to common stockholders was $6,300,000 $9,800,000 for the 3 months ended December 31, 2023, 2022, respectively. At December 31, 2023, we had cash and cash equivalents of approximately $126,600,000 I will also note that this afternoon, as customary for development stage companies in our sector, we filed a new shelf registration statement on Form S-three with the SEC to renew our previous S-three, which was set to expire next month. Shell's registration statements on Form S-three are standard in our industry are intended to provide us with broad flexibility to improve our balance sheet in the future as may be needed.

Speaker 3

As a reminder, Please refer to our quarterly report on Form 10 Q filed today with the SEC for additional details and disclosures. I will now turn the call back over to Sean.

Speaker 2

Thanks, Cindy. So as we wrap up today's call, I want to emphasize that we are very proud and very excited to be focused on reaching another key corporate milestone in the near term. That's the initiation of our PALISADE III Phase III trial of fastadienol for the acute treatment of anxiety in adults with SAD. We will progress through the next phases of our core corporate development strategies with confidence in our team's expertise to execute our PALISADE Phase 3 clinical program Fasadienol and SAD, the potential of our robust pipeline for multiple and diverse psychiatric and neurological disorders and our steadfast commitment to pioneering neuroscience to develop and commercialize truly differentiated treatment solutions. So on behalf of our whole team here at Vistigen, I want to thank you for your continued support.

Speaker 1

Thank you, Sean. Operator, we would now like to turn the call over for questions from the sell side analysts participating on the call today.

Operator

Our first question comes from the line of Paul Matteis with Stifel. Please proceed with your question.

Speaker 4

Hi, this is Julian on for Paul. Thanks so much for taking our question. Just a quick one for me. Are you still planning on doing a repeat dose study for fasodionol in SAB? And if so, would you be able to provide any color on that?

Speaker 4

Thanks so much.

Speaker 2

You bet. Thanks, Julian. Yeah, we are going to do a repeat dose study. It will be similar in design to PALISADE 3 and to PALCADE 4 and thus obviously by extension PALCADE 2. It will be smaller and it will assess the safety and potential benefit of a second dose of fastodionol that is administered within 10 minutes after the first dose and prior to public speaking challenge.

Speaker 2

So similar study design, similar endpoint, obviously much smaller. And the results of that study, part of it is in agreement with FDA, and especially as to any potential safety issue, which we don't anticipate any with repeat dosing. But it really could inform the labeling and provide some guidance as to whether or not a second dose administered within 10 minutes, which might be the case in a real world setting, is safe and as we anticipated could be again could provide any potential benefit for some patients. So We'll prepare to initiate that study in the second half of this year as we've guided.

Speaker 4

Excellent. Thanks so much.

Operator

Our next question comes from the line of Andrew Tsai with Jefferies.

Speaker 5

So maybe the first one on PALISADE III, 4, you're employing obviously some studying improvements to those programs. So could it be Fair to assume that the SUD separation in those studies could be even greater than what you saw in PALISADE II because As you're mitigating for placebo effect, could you be further maximizing the drug effect?

Speaker 2

Thanks. Well, thanks Andrew. As you mentioned, I mean we've done quite a few things to further de risk, the Phase 3 program and a lot of lessons learned on the other side of the prior studies and obviously this is not now a study design and an endpoint that sites and investigators seeing after a pretty long hiatus in the space of a couple of decades. So the things that we've done to improve Surveillance improve and further derisk execution of the program, certainly that's a possibility. But there are a lot of things.

Speaker 2

If you compare the world in 2022 to where we are today in 2024, just at a minimum taking masks out of the equation is a big difference. Having the ability to have in person investigator meetings, having the ability to do things that ensure rigorous adherence to the protocol, very exacting requirements of that protocol across sites. All of those things combined have the potential of course to improve even on what we in the past in Phase II and in PALISADE II. Josh, Prince, you want to add anything to that?

Speaker 4

Sure, Sean. Thank you. Yes, I think we're very optimistic about our ability to execute a well controlled study Post pandemic, and it's everything that you talked about, but it's also, the things that we're able to do in terms of how we Work with our CRO. We're putting feet on the ground in terms of our own monitors going to sites in addition to CRO monitors. We have some additional exclusion criteria to make sure that subjects that are coming into the study have the best chance to have positive results or opportunity to have positive results with fastadienal And even things such as eligibility review, making sure that subjects are appropriate subjects before they're going to the VISIT II and VISIT III public speaking challenges.

Speaker 4

So you put all those things together and it does give us a fair amount of optimism moving into PAL III and PAL IV to what we had when we were executing PALSAID I and PALSAID II.

Speaker 5

Thanks. And Maybe a follow-up on the repeat dose study that you're initiating in second half. As we think about the three arms, What are you and the FDA looking for? Or said in another way, what is positive data to you?

Speaker 2

Josh, go ahead and address that.

Speaker 4

Yes. We expect it to be a smaller study. It's not at this point, we don't expect to see power for statistical significance like you would in the PALISADE 3 OR PALISADE 4, but it would give us is, is there any indication that for some patients An additional dose within 10 minutes could provide some benefit, and that essentially can inform the label. So that I mean, At the end of the day, for us positive study is we either see that there is some indication that it could be a benefit or We don't, but either way there's benefit from the first dose.

Speaker 2

Yes. Again, it's really The discussions have been circled around informing labeling downstream and also real world understanding and some of that taken from open label activity where people might think a more is better within a short period of time. So first and foremost, we have to check the box on safety, which Again, we don't think there's much of if any risk there associated with a second dose within that 10 minute window. For those who don't know, it's there's 3 arms before a public speaking challenge, placebo, placebo, drug, placebo, drug, drug, drug, each of the second doses within 10 minutes of the first. And that's upfront of public speaking challenges.

Speaker 2

So again, taking into account possibilities in the real world that people will use the drug couple of times rather than staggered as the 15 minute study paradigm required or showed. So We'll see how it goes. Again, it's a dialogue. It's nice to be knowing we're talking about potential labeling benefits. So That's how we took it.

Speaker 2

Remember, these receptors are activated in milliseconds. So it's it doesn't take much time to get them moving in the first instance.

Speaker 5

Thank you very much.

Operator

Our next question comes from the line of Tim Lugo with William Blair. Please proceed with your question.

Speaker 6

Thanks for the question and congratulations And with the positive PAL-two trial, could you look to gain breakthrough status with the agency? Is it something you're exploring? Will this if you were to get breakthrough status, is it something that could impact your development path at all? And in your discussions with the agency, Do you have enough, maybe, I guess, preclinical data around abusability We're enough animal data around the feasibility to have that included in the label?

Speaker 2

Thanks, Tim. Appreciate those questions. So first as to BTD or breakthrough, look, that's always an aspiration of any company that's got something in a space that we've got. It's always an efficacy matter with the agency. I think look like I said, we just got done doing something don't think anybody else has ever done that we've seen and we certainly got a product profile potential that is different than anything that we see out there.

Speaker 2

We know the agency is worried about the potential high abuse of Benzodiazepines Unfortunately, social anxiety disorder and other anxiety disorders lead to depression and then lead Unfortunately, with increasing prevalence that we are seeing to suicidal ideation. So it's we already know we have Fast Track. Doesn't mean that you necessarily fall into breakthrough, but certainly something on our mind. And you're right too that It is important whether or not we see this drug is potentially being scheduled. As we addressed a while back, Especially with a drug that is administered intranasally, one might think, well, is it is there some abuse potential there?

Speaker 2

As we know from the preclinical work we've done and that we submitted to the FDA, and also clinical work, A large body of work including the open label study about 500 subjects with over 30,000 doses, We just were not seeing, the TEAEs or any certainly no SAEs that are usually associated with abuse liability even in the longer term open label. Mechanistically, it makes sense because The drug isn't taken up systemically and most importantly based on the GABA study that we did pre clinically and the C14 studies that we did, There's not tissue distribution and direct activity on the abuse liability receptors in the brain, opiate, nicotine, dopamine and the like. And and not potentiating GABA like say a benzo would also worked in our favor. So I think we're very confident as we continue to see Clinical data support the preclinical data and the whole package that says this is a differentiated safety profile because of the MOA. We're confident in a go forward where patients could have the ability to access the drug online on a recurring basis the drug potentially not being scheduled, no REMS.

Speaker 2

So we'll see how that continues to go. But what we saw in PALCID II, Again, no TEA more prevalent than 2%. In the large open label study, Nothing more prevalent than 5% other than headache at 8.7%. So that's remarkably different than what we often hear when we're listening to commercials and side effects that are associated with particular therapeutic options.

Speaker 6

Great. Thank you.

Operator

There are no further questions in the queue. I'd like to hand the call back to Mark McPartland for closing remarks.

Speaker 1

Thank you again everyone for participating on the call today. Again, if you have any additional questions, please do not hesitate to contact us by email at irvistigen.com or contacting the individuals listed in our press release issued earlier today or the contact section of our website. Again, we also encourage you to register for email updates on our website to stay connected with the latest news from and any future events. Thank you for participating on the call today. We appreciate everyone's interest and support.

Operator

Ladies and gentlemen, this does conclude today's teleconference. Thank you for your participation. You may disconnect your lines at this time

Remove Ads
Powered by Quartr
Earnings Conference Call
Vistagen Therapeutics Q3 2024
00:00 / 00:00
Remove Ads